Development of Sorbitan Monostearate organogels for controlled delivery systems. by Singh, Meenakshi
 DEVELOPMENT OF SORBITAN MONOSTEARATE ORGANOGELS 
FOR CONTROLLED DELIVERY SYSTEMS 
 
A THESIS SUBMITTED IN PARTIAL FULFILLMENT 
OF THE REQUIREMENTS FOR THE DEGREE OF 
 
Bachelor of Technology (Biomedical Engineering) 
 
Submitted  
By 
 
MEENAKSHI SINGH 
Roll No. 107BM008 
 
Under the Guidance of 
Dr. Kunal Pal 
 
 
 
 
Department of Biotechnology & Medical Engineering 
 National Institute of Technology 
 Rourkela 769008 
 
 
 
 
2 
 
 
DEPARTMENT OF BIOTECHNOLOGY & MEDICAL ENGINEERING, 
NATIONAL INSTITUTE OF TECHNOLOGY-ROURKELA 
                                                           Dated: May 14, 2011 
 
CERTIFICATE 
 
This is to certify that the thesis entitled “DEVELOPMENT OF SORBITAN 
MONOSTEARATE ORGANOGELS FOR CONTROLLED DELIVERY SYSTEMS” 
submitted by Ms. MEENAKSHI SINGH in partial fulfilment for the requirements for the 
award of Bachelor of Technology Degree in Biotechnology at National Institute of Technology, 
Rourkela is an authentic work carried out by him under the supervision of the undersigned.  
To the best of my knowledge, the matter embodied in the thesis has not been submitted to any 
other University / Institute for the award of any Degree or Diploma. 
 
 
 
(Dr. KUNAL PAL) 
Assistant Professor 
 
 
 
 
 
3 
 
ACKNOWLEDGEMENT 
 
 
I would like to express my deep sense of gratitude and respect to our supervisor, Dr. Kunal Pal, 
for his excellent guidance, suggestions and constructive criticism. I extend my gratitude to all 
staff members of Department of Biotechnology and Medical Engineering, NIT, Rourkela, for 
extending their help, as and when required.  I would like to thank my parents and friends, 
without whose unconditional love and support, this work would not have been possible. 
Last but not the least, I would like to extend my heartfelt gratitude to the M.Tech and Ph.D 
students of Department of Biotechnology and Medical Engineering, NIT, Rourkela whose ever 
helping nature and suggestions has helped me to complete this present work.  
 
. 
Meenakshi Singh. 
Roll no.: 107BM008. 
 
 
 
 
  
 
 
 
4 
 
ABSTRACT 
 
The study describes the development of sorbitan monostearate (Span 60) based organogels with 
mustard oil as the solvent.  Different compositions of organogels were prepared by varying the 
concentrations of span 60. During the preparation of organogels, their microstructures were 
studied under compound light microscope. The formulated organogels were characterized by 
light microscopy,   gel-to-sol transition temperature, long-term stability, pH, opacity 
measurements and hemocompatibilty studies. Metronidazole was incorporated within the 
organogels and its release behaviour was determined. The anti-microbial action of the drug-
loaded organogels on E. coli was studied. The microscopy of the organogels suggests that a 
three-dimensional network of rod-like tubular aggregates of gelator is responsible for 
immobilising the solvent.  Clusters of span 60 are visualised as dispersed in the liquid phase. The 
rate of formation of organogels and the release rate of metronidazole from the organogels was 
found to depend on span 60 proportions in the formulated organogels. The pH of the samples 
was found to be in the range of 6.4-7.1. The organogels were found to be hemocompatible in 
nature indicating their probable use as controlled delivery vehicles. 
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               Chapter 1 
1. INTRODUCTION 
The word “gel” has been derived from the Greek word, gelatus, which means “to immobilise”. 
In general, gels contain two components, one of which is a liquid and the other, a solid. The 
solid components form a three-dimensional networked structure which helps in immobilising the 
liquid component. The solid components are often regarded as gelators. Depending on the 
polarity of the liquid component, the gels may be regarded either as hydrogels (Polar phase) or 
organogels (Apolar phase). The immobilisation of the liquid within the three-dimensional 
network structure has been attributed to the surface active phenomena amongst the solid and the 
liquid phases. 
As the name organogel suggests, organogels contain apolar solvents (e.g. kerosene oil, sunflower 
oil, mustard oil, mineral oil) as the continuous phase. Organogels may be developed by two 
mechanisms, namely, fluid-fibre mechanism and solid-fibre mechanism. The fluid fibre 
mechanism involves the development of reverse-miscellar structures when water is added to a 
solution of surfactant in apolar solvent. The reverse miscellar structures undergo modification 
when further amount of water is added to the system, and in turn, undergoes physical interaction 
amongst each other to give rise to a three-dimensional network structure. Since, the three 
dimensional structures which are formed are made up of basic structures which contain a polar 
liquid phase, the mechanism of formation of formation is regarded as fluid-filled fibre 
mechanism. The networked structures formed in turn, help in immobilising the apolar solvent. 
On the other hand, solid-fibre mechanism deals with the dissolution of solid organogelators in 
hot apolar solvent to give rise to a homogeneous solution. The solution, so obtained, is cooled 
down to room temperature. This results in the change in the solubility parameter of the 
organogelator, thereby, resulting in the precipitation of the organogelators. The precipitated 
organogelators start forming fibre-like structures which undergo interaction amongst each other 
to form a three-dimensional networked structure. The fibres, which are formed, are basically 
made up of organogelator molecules and do not contain any liquid phase. Hence, these type of 
organogels are said to be formed by solid-fibre mechanism. Similar to the fluid-fibre 
mechanism, the three-dimensional structure formed by the solid organogelators help in 
immobilising the liquid apolar phase.  
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Span 60 (sorbitan monostearate) has long been used in various cosmetic, food and 
pharmaceutical applications due to its ability to act as a structuring agent. It has been found that 
the span 60 based matrices have the ability to modulate the release property of the bioactive 
agents (e.g. oligopeptides, polypeptides, cyclosporin, and salicylic acid). The matrices of the 
span 60 based formulations are formed by solid-fibre mechanism. Their use in the above-
mentioned industries has been increasing exponentially due to the easy formation of gelled 
structure, which have also been found to be thermodynamically stable for a prolonged period of 
time.  
Mustard oil, obtained from the seeds of Brassica nigra, has been traditionally used in house-hold 
cooking. Apart from its utility in cooking, it has also been used in various clinical conditions due 
to its anti-microbial, rubefacient and anti-cancer activities. But, now-a-days, its use in clinical 
conditions is decreasing because of the difficulty in handling the oil, typically, spillage of the oil 
or breakage of the container. This may be overcome by structuring the mustard oil using a 
suitable organogelator. Hence, in the present study, attempts were made to use span 60 as the 
organogelator to modify the texture of the mustard oil. The gels which were developed were 
characterised thoroughly to figure out its suitability to be used as a drug-delivery vehicle.  
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              Chapter 2 
2. REVIEW OF LITERATURE 
2.1 OVERVIEW OF DRUG DELIVERY 
Drug delivery refers to the application or, incorporation of pharmacologically-active agents 
(PAAs) to treat the symptoms of a disease. Drug delivery systems refer to the various methods 
and approaches used for the administration of PAAs to the targeted sites. Typically, 
pharmaceutical formulations consist of simple, fast-acting chemical compounds that are 
administered either non-invasively (non-invasive routes being oral, transdermal, nasal, rectal, 
vaginal and inhalational) or invasively[1], through injectables and implantable devices. The 
major drawback of conventional DDS is that the drug has to be administered at regular intervals 
of time in order to attain and maintain the minimum effective concentration (MEC) required in 
the systemic circulation to relieve the clinical manifestations of any given disease. The drug 
dosage at any given time should not cross the maximum therapeutic level (MTL), which defines 
the maximum concentration of the drug beyond which there is not much increase in the potency 
of the drug, though the risk of harmful side-effects considerably increases. Hence, the drug 
levels in the systemic circulation at any given time should be desirably maintained between the 
MEC and the MPL. This proves to be a challenging task because in most of the cases the 
concentration range between the MEC and the toxic dosage level is very narrow. In the typical 
DDS, the administered drugs deliver treatment continuously, rather than alleviating symptoms 
and preventing harmful outcomes solely as and when necessary. Also, in the current methods of 
drug delivery, many drugs’ therapeutic effects are limited or reduced because of the partial loss 
of the drug due to biochemical degradation inside the body that occurs before they reach a 
desired target site.  
In order to combat some of the drawbacks of typical DDS, scientists are actively developing 
controlled DDS, which maintain drug levels at the desired concentration levels, hence reducing 
the chances of under or overdose of the drug. The release profile of an ideal DDS should be 
flexible enough to adjust to any changes in the physiological requirements. The ultimate aim of 
all modern and recently developed drug delivery systems is to transport an incorporated drug or 
bioactive compound in its intact and active form to specifically targeted parts of the body 
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through a medium that can control the formulation’s administration by means of either a 
physiological or chemical trigger.[2] 
Intensive research in the last few years has proved  that  efficient and useful controlled release 
and delivery systems range from true nanosystems  (e.g., patterned nanoparticles) to those in the 
micron  range  (e.g., ~100 µm polymer-coated beads).  Delivery systems are divided  into nano-, 
micro- and  macro-delivery  systems  based  on  the  size  of  the  device  used. Examples of  
nano-delivery  systems  include  solid  lipid  nanoparticles,  dendrimers,  liposomes  and  
microemulsions. Micro- delivery systems include micro-particles of varying compositions.  
Finally, macro-delivery systems include hydrogels, organogels, tablets and capsules. 
 
2.2 GELS 
 
Gels may be defined as an intermediate state of matter, comprised of both the liquid as well as 
solid components. A three-dimensional interconnected network of solid molecules or aggregates 
is responsible for immobilizing the liquid continuous phase[3]. Physical interactions or covalent 
bonding among the gelator molecules result in the formation of a three-dimensional network. 
Heating of the physical gels increases the thermal energy of the gelled systems leading to the 
destruction of the physical interactions (hydrogen bonds, Van der Waals interactions) among the 
gelator molecules responsible for holding the gel together in the stable form. The temperature at 
which the physical gels lose their structural integrity is known as the gel-to-sol-transition 
temperature (Tg). However, because the physical forces holding the gel together are re-activated 
as the gels are cooled down, hence, these gelled systems revert back to their original stable form 
as the temperature is lowered below their Tg [3]. The gel-to-sol-transition temperature is 
dependent on the properties of the gelator molecules- both physical as well as chemical, the 
naure of the solvent and the concentration of both. For the determination of Tg, various visual 
inspection methods like, bubble motion[4], inverted test-tube method[5], “dropping-ball” 
technique[6] have been reported. Chemical bonding among the gelator molecules gives rise to 
permanent gels, which do not undergo gel-to-sol transition even when their temperature is 
raised. Therefore, gels may be classified on the basis of the type of the nature of the bonds 
responsible for the three-dimensional network e.g. strong covalent bonds within the network 
give rise to stable chemical gels whereas physical gels are formed when weaker forces like 
hydrogen  bonds  and  electrostatic  and  van  der  Waals interactions are responsible for 
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maintaining the solid network[3]. Moreover, if the classification is done on the basis of the 
liquid phase involved, gels can be broadly subdivided into hydrogels and organogels. Hydrogels 
have water as their dispersion medium whereas organogels have an organic solvent as the 
continuous liquid phase. 
 
Organogels are semi-solid systems in which a three-dimensional network of gelator molecules 
or aggregates immobilise an organic liquid continuous phase, typically an apolar solvent or 
oil[7]. The skeleton of the gelled structure consists of either polymers or low molecular weight 
organogelators. These form a cross-linked structure either by physical or chemical interactions, 
thereby immobilising the organic phase within the network. Molecular interactions such as 
hydrogen bonding, metal coordination or dipolar interactions are responsible for the organogel 
structure[3]. Organogels are viscoelastic systems, having both viscous and elastic properties. 
Physical organogels, which behave like solids at lower shear rates, start flowing as the shear 
stress is increased. This flow is attributed to the weakening and subsequent disruption of the 
physical bonds holding the three-dimensional network together as the shear force increases, 
resulting in the plastic flow behaviour of such organogels.[8]  
 
Some organogelators (e.g., lecithin) have been observed to undergo gelation in the presence of 
small amounts of water[8] (fluid-fiber containing organogels). The presence of trace amounts of 
water results in an exponential rise in the viscosity of the gelled systems as observed in the case 
of lecithin oraganogels- Addition of water to the apolar solution of lecithin increases the inherent 
viscosity by a factor of 104-106.[8, 9]. Entanglement of the fluid-fiber structures (tubular reverse 
micelles) result in the formation of rigid structures which might be responsible for the observed 
increase in viscosity. In solid-fiber containing organogels, a higher temperature is required for 
the dissolution of organogelator molecules in the apolar solvents. A decrease in temperature 
causes precipitation of the organogelator molecules and the subsequent physical interactions 
among the same result in the increased viscosity of the system. 
 
Thermoreversibilty, a characteristic property of physical gels, is observed in case of organogels 
too.  As discussed above, heating of the organogels increases the thermal energy of the gelled 
systems leading to the disruption of the physical interactions (hydrogen bonds, Van der Waals 
interactions) among the gelator molecules, and hence, it starts flowing. The temperature at which 
the organogels lose their structural integrity is known as the gel-to-sol-transition temperature 
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(Tg). However, because the physical forces holding the gel together are re-activated as the gels 
are cooled down, hence, these gelled systems revert back to their original stable form as the 
temperature is lowered below their Tg. 
Under appropriate conditions of temperature and concentration, the gelator molecules undergo 
self-assembly (leading to aggregates formation) which subsequently gives rise to a three-
dimensional solid network. The decrease in the total free energy of the system associated with 
the self-assembly of the organogelator molecules is responsible for the inherent thermostable 
nature of the organogels. Their thermostable nature has been utilised in the pharmaceutical 
industry by using organogels as sustained drug-delivery agents, where a longer shelf-life is 
required.[10] 
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              Chapter 3 
3. MATERIALS AND METHODS 
 
3.1 MATERIALS 
Span 60 was procured from Loba Chemie, Mumbai, India. Nutrient agar was obtained from 
Microlife, Delhi, India. Metronidazole was a gift from Aarti drugs, Mumbai, India. Edible 
mustard oil was procured from the local market. Double distilled water was used throughout the 
studies.  
 
3.2 PREPARATION OF ORGANOGELS 
The organogels were developed by varying the proportions of mustard oil and span 60. The 
proportion of the span 60 was increased up to 23% of the total organogel amount. The samples 
were prepared by dissolving specific weight of span 60 in mustard oil, kept at 70 oC and stirred 
at 100 rpm until a homogeneous solution was obtained.  The solution, so obtained, was allowed 
to cool down to 25 oC in a temperature controlled cabinet. The critical gelation concentration 
(CGC) of the span 60 was determined. The samples were stored at room temperature for further 
analysis.  
 
3.3 MICROSCOPIC STUDIES 
The samples of the organogels were analysed under compound light microscope (CH20i, 
Olympus India Pvt. Ltd., India). The organogels were heated to 70 oC and allowed to cool at 
room temperature. Sequential micrographs were taken till the temperature reached to room 
temperature. This study was conducted to understand the crystal growth of the organogels during 
the cooling of the hot homogeneous solution. 
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3.4 GEL-to-SOL TRANSITION 
Gel-sol transition temperature was found out by incubating the organogels in a water-bath, 
whose temperature was varied between 30-70 ºC. The temperature of the water bath was 
increased with an increment step of 5 oC and the gels were kept at the corresponding temperature 
for 5 minutes. In order to determine any induced flow, the organogels were analysed by 
inverting test-tube method before further increasing the temperature of the water bath. The 
temperature, at which the gels started to flow, when the glass vials were inverted, was noted as 
the gel-sol transition. 
 
3.5 STABILITY ANALYSIS OF THE ORGANOGELS 
The stability of the pharmaceutical products may be carried out by incubating the samples at a 
particular environment for a longer time period. ICH guidelines of stability of pharmaceutical 
products indicates the storage of the products at 30°C ± 2°C/65% RH ± 5% RH for 6 months 
(intermediate accelerated stability test). Apart from the above, samples were also kept at 5 oC and 40 
oC.  
 
3.6 pH MEASUREMENT 
The pH of the organogels was measured using a digital pH meter (ATC pH meter, MODEL 
132E). The probe was kept in contact with the organogel samples and the corresponding pH 
reading was noted down. 
 
3.7 OPACITY MEASUREMENTS 
The organogels were heated at 60 oC and were subsequently cooled down at room-temperature. 
The turbidity of the solution was measured using colorimeter (EI-D10 Digital Photocolorimeter). 
The change in temperature of the solution was monitored using a digital thermometer (MexTech 
multithermometer) and the corresponding absorbance was recorded at 420 nm.  
In a similar experiment, the turbidity of the organogels were analysed as a function of time.  
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3.8 HEMOCOMPATIBILITY 
The hemocompatibility tests were done as per the modified ASTM protocol, which figures out 
the extent of hemolysis in the presence of the samples. The organogels were put in dialysis bags, 
which were put in 50 ml of saline solution for 30 min. 0.5 ml of the dialysate was used for the 
test. For this purpose, fresh goat’s blood is collected in the presence of sodium citrate 
(anticoagulant). 8 ml of the citrated blood is diluted to 18 ml with saline solution.  0.5 ml of the 
diluted blood is taken in a centrifuge tube followed by the addition of the 0.5 ml of the test 
solution. The final volume was made up to 10 ml. For positive control, 0.5 ml of diluted blood is 
mixed with 0.01 N HCl and subsequently diluted to 10 ml. For negative control, 0.5 ml of blood 
is diluted to 10 ml with saline solution. The centrifuge tubes are incubated at 37 oC for 60 min. 
The % hemolysis is calculated as per the following formula: 
% 100test Negative
positive Negative
OD OD
Hemolysis
OD OD
−
= ×
−
 
If the % hemolysis is <5 then the material is considered as highly hemocompatible, a value <10 
indicates hemocompatible whereas a value > 20 indicates non-hemocompatible. 
 
3.9 ANTI-MICROBIAL STUDIES 
Gram negative bacteria E. coli was used for antimicrobial study. Nutrient agar solid medium was 
used for the study. 1 ml of cell suspension (containing 10-6 to10-7 cfu/ml) in water was spread 
over the surface of the nutrient solid agar media. Wells of 9 mm diameter were made into the 
agar plates using a borer so as to accommodate 0.5 g of antimicrobial drug loaded organogel. 
The petri-dishes were incubated at 37 ºC for 24 h to allow the growth of the bacteria. The zone 
of inhibition was measured by using a ruler at the end of 24 h.  
 
3.10 IN-VITRO DRUG RELEASE STUDIES  
A two-compartment cell was used for the drug release study. The compartments were separated 
by the dialysis membrane (MW cutoff - 60 kDa, Himedia, Mumbai). The donor compartment 
contained 5 g of metronidazole loaded organogels while the receptor compartment contained 50 
ml of water. Then the donor compartment was lowered to ensure that the dialysis membrane 
touched the receptor fluid, kept on stirring at 100 rpm. For the first 1h, the 50 ml water was 
completely replaced with fresh 50 ml water at an interval of 15 min. Subsequently, the 
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replacement of the water was done at an interval of 30 min until 6 h. A portion of the replaced 
water was kept for further analysis under UV visible spectrometer (Shimadzu UV 1601 r) at a 
wavelength of 277 nm. All the experiments were carried out in duplicates. 
Attempts were also made to estimate what kind of model (e.g. zero-order, first-order and 
Higuchian models) the release pattern follows. The parameters (e.g. k and the determination 
coefficient r2) were calculated for predicting the release model. 
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               Chapter 4 
4. RESULTS AND DISCUSSION 
4.1 PREPARATION OF ORGANOGELS 
 
Accurately weighed span 60 was dissolved in mustard oil at 70 oC. The concentration of span 60 
was varied from 1% (w/w) to 22 % (w/w) in order to determine the critical gelling concentration 
(CGC). CGC is defined as the minimum concentration of the organogelator required to 
immobilize the solvent. The hot span 60 solution was subsequently cooled down at room-
temperature. As the temperature was decreased, there was a change in the solubility parameter of 
the span 60 molecules which resulted in the precipitation of the span 60 molecules in the oil 
continuous phase. The precipitation of the span 60 molecules made the solution cloudy. 
Depending on the concentration of the span 60 in oil, the solution either remained cloudy or 
formed an opaque solid-like structure. The samples were regarded as organogels, if the final 
product did not flow when the culture bottles were inverted[5] (Figure 1). The CGC of the span 
60 to immobilize the mustard oil was found to be 17 % (w/w). Below 17 % (w/w) concentration 
of span 60, the final product was a turbid solution, which started flowing when the culture 
bottles were inverted (Figure 2). The apparent viscosity of the turbid solutions was found to be 
increased as the concentration of span 60 increased up to the concentration of 17 % (w/w). At 17 
% (w/w) of span 60 concentration, the turbid solution started forming solid-like structure. All the 
gels were yellow in colour because of the inherent colour of mustard oil. They had a slight odour 
and were smooth and “oily” to touch. The composition of the organogels, which were used for 
further analysis have been tabulated in Table 1. It was observed that the organogels with higher 
proportions of span 60, attained the gel structure relatively quickly. 
 
 
 
 
 
 
 
 
Figure 1: Gelation process of organogel
 (a) clear solution after heating; (b) uniform, cloudy suspension upon cooling and standing; (c) 
opaque, semi-solid gel upon further standing.
 
Figure 2: With 12%(w/w) SMS in mustard oil 
(a) clear solution after heating; (b) turbid suspension upon cooling and standing; (c) Upon 
further standing, suspension flowing on inverting the culture bottle.
The composition of the organogels selected for further analysis is tabulated in Table 
formulated span 60 organogels have been shown in Figure 
 
(a) 
19 
 containing 18% (w/w) span 60 in mustard oil:
 
 
 
3. 
(b) (c) 
 
 
 
1. The 
 
 
 
 
 
 
Table 1: Composition of organogels selected for further analysis
Sample 
A 
B 
C 
D 
E 
F 
 
 
Figure 3: Span 60 based organogels
(a)A; 17%(w/w) (b)B; 18%(w/w) (c) C; 19%(w/w) (d) D; 20%(w/w) (e) E; 21%(w/w) (f) F; 
22%(w/w) 
 
4.2 MICROSCOPIC STUDIES
 
The process of gelation was monitored under a compound light microscope as the hot span 60 
solution in mustard oil is cooled at room
underlying phenomena of gel formation. The micrographs showed the presence of gelator 
20 
 
Span 60 concentration 
(%, w/w) 
17 
18 
19 
20 
21 
22 
: 
 
-temperature (figure 4). This was done to understand the 
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molecules dispersed in the liquid phase. The gelator molecules self-assemble into aggregates as 
the samples cool down. These clusters of gelator molecules resemble rod-like tubular structures. 
These tubular aggregates continue associating with each other (figure 4), as the temperature 
decreases thereby resulting in the formation of a three-dimensional network. This solid skeleton 
of gelator aggregates is responsible for immobilising the liquid phase and giving rise to a gel.[3] 
The effect of gelator concentration was also visualized on the cloudy solutions and the 
organogels. As the gelator concentration was increased up to the CGC, there was an increase in 
the tubular structures without any formation of the three-dimensional networked structures 
(Figure 5). As the gelator concentration was increased beyond the CGC, the density of the 
gelator aggregates or tubular structures forming the networked structure increased (Figure 6). 
This can be attributed to the increased number of gelator molecules in a given volume of oil. 
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                             (a)                                                (b)            
 
 (c) 
Figure 4: Organogel microstructure at different time points. Sequential micrographs (a−c) show 
the change in organogel microstructure: (A) Molten condition; t = 0 (B) At t = 1 min. (C) At t = 
3 min.  
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Figure 5: Microstructures for samples with SMS in mustard oil below CGC.  
Span 60 conc. being (a) 2%(w/w) (b) 5%(w/w) (c) 8%(w/w) (d) 10%(w/w) (e) 12%(w/w) (f) 
15%(w/w)  
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Figure 6: Microstructures for different organogel samples (a) A (b) B (c) C (d) D (e) E and (f) F. 
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4.3 GEL-SOL TRANSITION ANALYSIS 
 
The organogels were subjected to increasing temperatures starting from 30 ºC. An increment of 
5 ºC was made after 5 min incubation at the previous temperature. The samples were considered 
to have undergone gel-sol transition when they started to flow when the culture bottles were 
inverted.[5] 
The rise in temperature results in the increase in surface active energy with a subsequent 
increase in the mobility of the self-assembled aggregates formed by the gelator molecules. With 
the further increase in temperature, the absorbed thermal energy interferes with the molecular 
interactions amongst the self-assembled aggregates, which are responsible for the three-
dimensional network structure of the organogels. The subsequent disruption of the networked 
structure causes the system to flow freely (figure 7). The concentration of span 60 in the range of 
17 % and 22 % (w/w) in the organogels did not affect the gel-to-sol transition temperature (table 
2).  
 
Table 2: Gel-to-Sol transition observations 
Sample Gel-sol transition temperature 
(oC) 
A 50 
B 50 
C 50 
D 50 
E 50 
F 50 
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Figure 7: Gelation process of organogel containing 18% (w/w) SMS in mustard oil: 
(a) clear solution after heating; (b) uniform, cloudy suspension upon cooling and standing; (c) 
opaque, semi-solid gel upon further standing.  
 
4.4 GEL STABILITY ANALYSIS 
 
The duration of the time period for which a gel remains intact (i.e. without the separation of the 
solid and the liquid phases) when stored in sealed vessels at room temperature is known as a 
gel’s lifetime[3]. In order to determine the lifetime of the organogels under different 
environmental conditions, the samples were kept at 5 oC, 40 oC and at ambient temperatures. The 
observations of the study are tabulated in Table no. With the gel lifetime being less than a week, 
it was found that the storage of the organogels at 40 oC induced early destabilisation in the 
samples. The samples stored at ambient temperatures were found to possess intermediate 
stability whereas the samples stored at 5 oC were stable for longer periods of time (6 months, 
Refer Table 3). The results of the study indicate that, in order to prolong the shelf-life of the 
organogels, they should be preferably stored at lower temperatures. Their longer, stable lifetime 
will encourage their use as drug-delivery vehicles in the pharmaceutical industries.[11] 
  
(a) (b) (c) 
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Table 3: Observations of the stability test 
 
Sample 
Destabilization time (days) 
Ambient  temperature At  5 oC At 40 oC 
A 4 months 6 months 2 days 
B 4 months 6 months 2 days 
C 4 months 6 months 2 days 
D 4 months 6 months 2 days 
E 4 months 6 months 2 days 
F 4 months 6 months 2 days 
 
 
4.5 PH MEASUREMENT 
 
The pH of the biomedical products is a significant characteristic of the formulations as these 
products are supposed to be in contact with the human tissues. Any variation from the 
physiological pH may lead to the irritation of the cells, which in turn might cause immunological 
reactions (e.g. redness, burning and itching of the skin in the applied area)[3]. For this reason, 
US pharmacopoeia has set pH standards for transdermal and topical formulations. The pH of the 
organogels was measured at room temperature by using electrode based digital pH meter. The 
pH values for all samples given in table 4. The tested samples had different concentrations of the 
span 60 and efforts were made to correlate the pH with the varying gelator concentrations. 
However, the pH of the samples did not follow any specific trend with respect to the 
organogelator concentration or any other component in the gel. The pH of the organogel samples 
was found to be in between 6.4-7.10, indicating their probable use in the formulation of the 
transdermal or topical products.  
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Table 4: pH values of organogels 
Sample No pH  
A 6.78 
B 6.42 
C 6.85 
D 7.07 
E 7.10 
F 6.54 
 
 
4.6 OPACITY DETERMINATION 
 
The changes in the absorbance of the organogels as the hot solutions were cooled at room-
temperature have been shown in Figure 8. It was found that at the same temperature, the sample 
with higher concentration of span 60 showed a higher absorbance than that of the sample with 
lower concentration of the organogelator. Also, the sample with higher concentration reached the 
saturation value at a higher temperature indicating that the rate of precipitation of the span 60 is 
higher in those samples. This result supports the observation of quick gelling of the solvent as 
the span 60 concentration is increased. 
The change in the absorbance of the hot solutions as a function of time has been shown in Figure 
9. The results indicate that as the gelator concentration was increased, the absorbance of the 
solution was higher at a particular instance of time. This suggests that as the solutions are cooled 
at room-temperature, the rate of precipitation of the gelator is higher in samples with higher 
organogelators.    
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Figure 8: The change in the absorbance values of the different compositions of organogel 
samples as a function of temperature.  
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Figure 9: The change in the absorbance values of the different compositions of organogel 
samples as a function of time 
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4.7 ANTIMICROBIAL TEST  
 
Metronidazole was incorporated within the organogel D, with concentration of span 60 in 
mustard oil being 20% (w/w). A bore of 9 mm diameter was made in the nutrient agar plates 
containing the specific microorganism, E. coli. The organogel without drug acted as a control 
loaded whereas the organogel loaded with drug served as the active sample. It was found that the 
bioactive agent was able to eliminate specific microorganism within a given area and did not 
allow the growth of the microorganism even after 24 h (Table 5). On the other hand, control 
organogel samples did not show any zone of inhibition. This indicates that the organogels may 
be tried as a controlled delivery system, where it may deliver the bioactive agent for a prolonged 
period of time. 
Table 5: Zone of inhibition 
 
 
4.8 IN-VITRO DRUG RELEASE STUDY  
 
The release profiles of the drug from the organogels have been shown in figure 9. The low 
CPDR value indicates the controlled release behaviour of the formulation and is reckoned to be 
the feature of amphiphilogels. The CPDR values were observed to decrease with increasing 
sorbitan monostearate concentration. The diffusional drug release is dependent on the solid 
skeleton network formed by the gelator molecules. As the gelator aggregates or fibers are 
responsible for the three-dimensional structured network that immobilises the liquid phase, it 
might be reasoned that excessive cross-linking with higher amounts of the gelator, act as a 
hindrance to the passage of the drug out of the matrix and hence decreases the drug release. 
Figure 10 shows the CPDR values as a function of time. 
 
 
Bioactive agent 
 
Zone of inhibition(Diameter, cm) 
E. coli Control 
 
Metronidazole, 1%(w/w) 
1.8± 0.2 Nil 
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Table 6 shows the coefficients determined for different kinetic models of drug release. The 
release kinetics best-fit model indicated that the release of the drug from the organogels followed 
Higuchi Model kinetics indicating that the organogels may be used as controlled delivery 
systems. 
.
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Figure 10: CPDR values for different compositions of the organogel samples as a function of 
time 
 
 Table 6: Kinetics of drug release 
Sample Zero order First order Higuchi Model 
kinetics 
Best-fit 
Model 
r2 k r2 K r2 k 
A 0.9419 0.0252 0.8389 0.0028 0.9830 0.4949 Higuchi 
Model 
kinetics 
B 0.9334 0.02247 0.808 0.0025 0.9968 0.454 Higuchi 
Model 
kinetics 
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C 0.9370 0.019 0.8453 0.0024 0.9960 0.389 Higuchi 
Model 
kinetics 
D 0.9191 0.0161 0.85 0.0022 0.9961 0.321 Higuchi 
Model 
kinetics 
E 0.9131 0.0138 0.8683 0.002 0.9925 0.2757 Higuchi 
Model 
kinetics 
F 0.8782 0.01245 0.8340 0.0018 0.98672 0.2520 Higuchi 
Model 
kinetics 
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Figure 11: Higuchian-model kinetics for the different organogels samples (a) A (b) B (c) C (d)D 
(e)E (f) F. 
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4.9 HEMOCOMPATIBILITY 
 
The hemocompatibility of the samples have been tabulated in Table 7. The results indicate that 
the samples are highly haemocompatible in nature indicating its biocompatibility. Hence the 
organogel samples may be tried as a drug delivery vehicle. Table 7 shows the percentage 
hemolysis values obtained for the various samples. 
 
Table 7: Results of the Hemocompatibility test 
Sample % hemolysis 
A 1.26 
B 3.48 
C 4.74 
D 1.89 
E 5.06 
F 3.79 
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               Chapter 5 
5. CONCLUSIONS 
Organogels with varying proportions of sorbitan monostearate in mustard oil were prepared and 
their microstructures were successfully studied. The micrographs revealed the presence of rod-
like tubular structures which are clusters of span 60, formed by the self-assembly of gelator 
molecules as the temperature of the organogel samples decreases. These aggreagates form a 
three-dimensional network which is responsible for immobilising the solvent. It was also 
observed that the gelation occurred sooner in samples with higher span 60 concentrations. The 
gel-to-sol transition temperature for the organogel samples was found to be 50oC. The results of 
the gel stability studies indicate that, in order to have a longer shelf-life, the samples must be 
stored at cool places. The determination of opacity of the organogel samples confirm the 
microscopic observation that higher precipitation of gelator molecules occurs in samples with 
higher concentrations of the gelator. The formulated organogels were found to be highly 
hemocompatible. Metronidazole incorporated organogel samples showed anti-microbial studies 
against E.coli and it was found that the release of drug out of the gel matrix can be modulated by 
changing the span 60 concentrations.  
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